

Kiyohide Fujimoto

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7902473/publications.pdf>

Version: 2024-02-01

260
papers

3,445
citations

159585

30
h-index

254184

43
g-index

327
all docs

327
docs citations

327
times ranked

4556
citing authors

#	ARTICLE	IF	CITATIONS
1	CXCL1-Mediated Interaction of Cancer Cells with Tumor-Associated Macrophages and Cancer-Associated Fibroblasts Promotes Tumor Progression in Human Bladder Cancer. <i>Neoplasia</i> , 2016, 18, 636-646.	5.3	161
2	Collagen type IV alpha 1 (COL4A1) and collagen type XIII alpha 1 (COL13A1) produced in cancer cells promote tumor budding at the invasion front in human urothelial carcinoma of the bladder. <i>Oncotarget</i> , 2017, 8, 36099-36114.	1.8	76
3	Regulatory T Cells and Tumor-Associated Macrophages in the Tumor Microenvironment in Non-Muscle Invasive Bladder Cancer Treated with Intravesical Bacille Calmette-Guérin: A Long-Term Follow-Up Study of a Japanese Cohort. <i>International Journal of Molecular Sciences</i> , 2017, 18, 2186.	4.1	71
4	siRNA-mediated Knockdown of the Heme Synthesis and Degradation Pathways: Modulation of Treatment Effect of 5-aminolevulinic Acid-based Photodynamic Therapy in Urothelial Cancer Cell Lines. <i>Photochemistry and Photobiology</i> , 2009, 85, 1020-1027.	2.5	69
5	Clinical impact of postoperative loss in psoas major muscle and nutrition index after radical cystectomy for patients with urothelial carcinoma of the bladder. <i>BMC Cancer</i> , 2017, 17, 237.	2.6	68
6	Clinical Practice Guidelines for Bladder Cancer 2019 update by the Japanese Urological Association: Summary of the revision. <i>International Journal of Urology</i> , 2020, 27, 702-709.	1.0	65
7	Heme oxygenase-1 promotes angiogenesis in urothelial carcinoma of the urinary bladder. <i>Oncology Reports</i> , 2011, 25, 653-60.	2.6	64
8	Oral 5-aminolevulinic acid mediated photodynamic diagnosis using fluorescence cystoscopy for non-muscle-invasive bladder cancer: A randomized, double-blind, multicentre phase II/III study. <i>Photodiagnosis and Photodynamic Therapy</i> , 2015, 12, 193-200.	2.6	61
9	Oral 5-aminolevulinic acid-mediated photodynamic diagnosis using fluorescence cystoscopy for non-muscle-invasive bladder cancer: A multicenter phase III study. <i>International Journal of Urology</i> , 2018, 25, 723-729.	1.0	61
10	Integrative Assessment of Pretreatment Inflammation-, Nutrition-, and Muscle-Based Prognostic Markers in Patients with Muscle-Invasive Bladder Cancer Undergoing Radical Cystectomy. <i>Oncology</i> , 2017, 93, 259-269.	1.9	56
11	Syndecan-1 (<scp>CD138</scp>) contributes to prostate cancer progression by stabilizing tumour-initiating cells. <i>Journal of Pathology</i> , 2013, 231, 495-504.	4.5	48
12	Role of syndecan-1 (CD138) in cell survival of human urothelial carcinoma. <i>Cancer Science</i> , 2010, 101, 155-160.	3.9	47
13	Basic Fibroblast Growth Factor as a Candidate Tumor Marker for Renal Cell Carcinoma. <i>Japanese Journal of Cancer Research</i> , 1995, 86, 182-186.	1.7	46
14	Mycoplasma genitalium Infection and Chronic Inflammation in Human Prostate Cancer: Detection Using Prostatectomy and Needle Biopsy Specimens. <i>Cells</i> , 2019, 8, 212.	4.1	46
15	The Relationship Between Nocturnal Polyuria and the Distribution of Body Fluid: Assessment by Bioelectric Impedance Analysis. <i>Journal of Urology</i> , 2009, 181, 219-224.	0.4	45
16	A phase III multicenter, randomized, controlled study of combined androgen blockade with versus without zoledronic acid in prostate cancer patients with metastatic bone disease: results of the ZAPCA trial. <i>International Journal of Clinical Oncology</i> , 2017, 22, 166-173.	2.2	45
17	Neutrophil-to-lymphocyte ratio as a detection marker of tumor recurrence in patients with muscle-invasive bladder cancer after radical cystectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 257.e11-257.e17.	1.6	44
18	Immunohistochemical Analysis of Inflammatory Cells in Benign and Precancerous Lesions and Carcinoma of the Prostate. <i>Pathobiology</i> , 2013, 80, 119-126.	3.8	43

#	ARTICLE	IF	CITATIONS
19	Exploration of risk factors predicting outcomes for primary T1 high-grade bladder cancer and validation of the Spanish Urological Club for Oncological Treatment scoring model: Long-term follow-up experience at a single institute. <i>International Journal of Urology</i> , 2015, 22, 541-547.	1.0	43
20	microRNA-145 promotes differentiation in human urothelial carcinoma through down-regulation of syndecan-1. <i>BMC Cancer</i> , 2015, 15, 818.	2.6	42
21	Syndecan-1 responsive microRNA-126 and 149 regulate cell proliferation in prostate cancer. <i>Biochemical and Biophysical Research Communications</i> , 2015, 456, 183-189.	2.1	42
22	ALKBH2, a novel ALKB homologue, contributes to human bladder cancer progression by regulating MUC1 expression. <i>Cancer Science</i> , 2013, 104, 321-327.	3.9	41
23	Diagnostic markers of urothelial cancer based on DNA methylation analysis. <i>BMC Cancer</i> , 2013, 13, 275.	2.6	39
24	Syndecan-1 up-regulates microRNA-331-3p and mediates epithelial-to-mesenchymal transition in prostate cancer. <i>Molecular Carcinogenesis</i> , 2016, 55, 1378-1386.	2.7	39
25	Clinical Impact of Sarcopenia and Inflammatory/Nutritional Markers in Patients with Unresectable Metastatic Urothelial Carcinoma Treated with Pembrolizumab. <i>Diagnostics</i> , 2020, 10, 310.	2.6	38
26	Diagnostic and prognostic role of urinary collagens in primary human bladder cancer. <i>Cancer Science</i> , 2017, 108, 2221-2228.	3.9	36
27	Pro-chemotherapeutic effects of antibody against extracellular domain of claudin-4 in bladder cancer. <i>Cancer Letters</i> , 2015, 369, 212-221.	7.2	34
28	The clinical trial on the safety and effectiveness of the photodynamic diagnosis of non-muscle-invasive bladder cancer using fluorescent light-guided cystoscopy after oral administration of 5-aminolevulinic acid (5-ALA). <i>Photodiagnosis and Photodynamic Therapy</i> , 2016, 13, 91-96.	2.6	34
29	Clinical Significance of Heme Oxygenase-1 Expression in Non-Muscle-Invasive Bladder Cancer. <i>Urologia Internationalis</i> , 2010, 85, 355-363.	1.3	33
30	Relationship Between Nocturnal Urine Volume, Leg Edema, and Urinary Antidiuretic Hormone in Older Men. <i>Urology</i> , 2011, 77, 1426-1431.	1.0	33
31	Preoperative predictive factors focused on inflammation-, nutrition-, and muscle-status in patients with upper urinary tract urothelial carcinoma undergoing nephroureterectomy. <i>International Journal of Clinical Oncology</i> , 2019, 24, 533-545.	2.2	33
32	Periodical assessment of genitourinary and gastrointestinal toxicity in patients who underwent prostate low-dose-rate brachytherapy. <i>Radiation Oncology</i> , 2013, 8, 25.	2.7	31
33	Clinical significance and therapeutic potential of prostate cancer antigen-1/ALKBH3 in human renal cell carcinoma. <i>Oncology Reports</i> , 2015, 34, 648-654.	2.6	30
34	Variations in International Prostate Symptom Scores, Uroflowmetric Parameters, and Prostate Volume After 125I Permanent Brachytherapy for Localized Prostate Cancer. <i>Urology</i> , 2009, 74, 407-411.	1.0	29
35	Trends of the Primary Therapy for Patients with Prostate Cancer in Nara Uro-oncological Research Group (NUORG): A Comparison Between the CaPSURE Data and the NUORG Data. <i>Japanese Journal of Clinical Oncology</i> , 2010, 40, 588-592.	1.3	28
36	Diagnostic approach for cancer cells in urine sediments by 5-aminolevulinic acid-based photodynamic detection in bladder cancer. <i>Cancer Science</i> , 2014, 105, 616-622.	3.9	28

#	ARTICLE	IF	CITATIONS
37	Correlation of Immune Cells and Cytokines in the Tumor Microenvironment with Elevated Neutrophil-To-Lymphocyte Ratio in Blood: An Analysis of Muscle-Invasive Bladder Cancer. <i>Cancer Investigation</i> , 2018, 36, 395-405.	1.3	28
38	Emerging biomarkers for the diagnosis and monitoring of urothelial carcinoma. <i>Research and Reports in Urology</i> , 2018, Volume 10, 251-261.	1.0	27
39	5-fluorouracil enhances the antitumor effect of sorafenib and sunitinib in a xenograft model of human renal cell carcinoma. <i>Oncology Letters</i> , 2012, 3, 1195-1202.	1.8	25
40	Monoclonal Antibody against CXCL1 (HL2401) as a Novel Agent in Suppressing IL6 Expression and Tumoral Growth. <i>Theranostics</i> , 2019, 9, 853-867.	10.0	25
41	Clinical Practice Guidelines for Bladder Cancer 2019 edition by the Japanese Urological Association: Revision working position paper. <i>International Journal of Urology</i> , 2020, 27, 362-368.	1.0	25
42	Prostate diseases and microbiome in the prostate, gut, and urine. <i>Prostate International</i> , 2022, 10, 96-107.	2.3	25
43	A multiplex urinary immunoassay for bladder cancer detection: analysis of a Japanese cohort. <i>Journal of Translational Medicine</i> , 2016, 14, 287.	4.4	24
44	Expression of ferrochelatase has a strong correlation in protoporphyrin IX accumulation with photodynamic detection of bladder cancer. <i>Photodiagnosis and Photodynamic Therapy</i> , 2016, 13, 225-232.	2.6	23
45	Protoporphyrin IX induced by 5-aminolevulinic acid in bladder cancer cells in voided urine can be extracorporeally quantified using a spectrophotometer. <i>Photodiagnosis and Photodynamic Therapy</i> , 2015, 12, 282-288.	2.6	22
46	NACC1, as a Target of MicroRNA-331-3p, Regulates Cell Proliferation in Urothelial Carcinoma Cells. <i>Cancers</i> , 2018, 10, 347.	3.7	22
47	The biochemical recurrence-free rate in patients who underwent prostate low-dose-rate brachytherapy, using two different definitions. <i>Radiation Oncology</i> , 2014, 9, 107.	2.7	21
48	Review by urological pathologists improves the accuracy of Gleason grading by general pathologists. <i>BMC Urology</i> , 2015, 15, 70.	1.4	21
49	Tadalafil, a phosphodiesterase type 5 inhibitor, improves bladder blood supply and restores the initial phase of lower urinary tract dysfunction in diabetic rats. <i>Neurourology and Urodynamics</i> , 2018, 37, 666-672.	1.5	21
50	Dual benefit of supplementary oral 5-aminolevulinic acid to pelvic radiotherapy in a syngenic prostate cancer model. <i>Prostate</i> , 2019, 79, 340-351.	2.3	21
51	Gamma-Klotho exhibits multiple roles in tumor growth of human bladder cancer. <i>Oncotarget</i> , 2018, 9, 19508-19524.	1.8	21
52	Use of alpha-1 adrenoceptor antagonists in patients who underwent low-dose-rate brachytherapy for prostate cancer - a randomized controlled trial of silodosin versus naftopidil -. <i>Radiation Oncology</i> , 2014, 9, 302.	2.7	20
53	Clinical significance of β - and β -Klotho in urothelial carcinoma of the bladder. <i>Oncology Reports</i> , 2016, 36, 2117-2125.	2.6	20
54	Risk-stratified survival rates and predictors of biochemical recurrence after radical prostatectomy in a Nara, Japan, cohort study. <i>International Journal of Clinical Oncology</i> , 2011, 16, 553-559.	2.2	18

#	ARTICLE	IF	CITATIONS
55	Estimated functional renal parenchymal volume predicts the split renal function following renal surgery. <i>World Journal of Urology</i> , 2015, 33, 1571-1577.	2.2	18
56	Comparison of PSA value at last follow-up of patients who underwent low-dose rate brachytherapy and intensity-modulated radiation therapy for prostate cancer. <i>BMC Cancer</i> , 2017, 17, 573.	2.6	18
57	Photodynamic Diagnosis-Assisted Transurethral Resection Using Oral 5-Aminolevulinic Acid Decreases the Risk of Repeated Recurrence in Non-Muscle-Invasive Bladder Cancer: A Cumulative Incidence Analysis by the Person-Time Method. <i>Diagnostics</i> , 2021, 11, 185.	2.6	18
58	Non-maintenance intravesical Bacillus Calmette-Guérin induction therapy with eight doses in patients with high- or highest-risk non-muscle invasive bladder cancer: a retrospective non-randomized comparative study. <i>BMC Cancer</i> , 2021, 21, 266.	2.6	18
59	Photodynamic diagnosis of shed prostate cancer cells in voided urine treated with 5-aminolevulinic acid. <i>BMC Urology</i> , 2014, 14, 59.	1.4	17
60	The Impact of Obstructive Sleep Apnea Syndrome on Nocturnal Urine Production in Older Men With Nocturia. <i>Urology</i> , 2014, 84, 892-897.	1.0	17
61	Supplementary granulocyte macrophage colony-stimulating factor to chemotherapy and programmed death-1 blockade decreases local recurrence after surgery in bladder cancer. <i>Cancer Science</i> , 2019, 110, 3315-3327.	3.9	17
62	Low-dose-rate brachytherapy for prostate cancer: A 15-year experience in Japan. <i>International Journal of Urology</i> , 2020, 27, 17-23.	1.0	17
63	Salvage Radiotherapy Versus Hormone Therapy for Prostate-specific Antigen Failure After Radical Prostatectomy: A Randomised, Multicentre, Open-label, Phase 3 Trial (JCOG0401). <i>European Urology</i> , 2020, 77, 689-698.	1.9	17
64	A randomized phase III trial of personalized peptide vaccination for castration-resistant prostate cancer progressing after docetaxel. <i>Oncology Reports</i> , 2020, 45, 159-168.	2.6	17
65	Long-term effects of diabetes mellitus on voiding function in a new model of type 2 diabetes mellitus, the Spontaneously Diabetic Torii (SDT) rat. <i>Biomedical Research</i> , 2009, 30, 331-335.	0.9	16
66	Changes in oncological outcomes after radical nephroureterectomy in patients with upper urinary tract urothelial carcinoma treated in the last two decades: a retrospective analysis based on a multicenter collaborative study. <i>Japanese Journal of Clinical Oncology</i> , 2016, 46, 1148-1155.	1.3	16
67	Outcomes of subsequent non-muscle-invasive bladder cancer treated with intravesical Bacillus Calmette-Guérin after radical nephroureterectomy for upper urinary tract urothelial carcinoma. <i>BJU International</i> , 2018, 121, 764-773.	2.5	16
68	Second nationwide surveillance of bacterial pathogens in patients with acute uncomplicated cystitis conducted by Japanese Surveillance Committee from 2015 to 2016: antimicrobial susceptibility of <i>Escherichia coli</i> , <i>Klebsiella pneumoniae</i> , and <i>Staphylococcus saprophyticus</i> . <i>Journal of Infection and Chemotherapy</i> , 2019, 25, 413-422.	1.7	16
69	The third national Japanese antimicrobial susceptibility pattern surveillance program: Bacterial isolates from complicated urinary tract infection patients. <i>Journal of Infection and Chemotherapy</i> , 2020, 26, 418-428.	1.7	16
70	The best objective response of target lesions and the incidence of treatment-related hypertension are associated with the survival of patients with metastatic renal cell carcinoma treated with sunitinib: a Japanese retrospective study. <i>BMC Research Notes</i> , 2016, 9, 79.	1.4	15
71	Linkage of Lower Urinary Tract Symptoms to Sleep Quality in Elderly Men with Nocturia: A Community Based Study Using Home Measured Electroencephalogram Data. <i>Journal of Urology</i> , 2017, 197, 204-209.	0.4	15
72	Assessment of lower urinary symptom flare with overactive bladder symptom score and International Prostate Symptom Score in patients treated with iodine-125 implant brachytherapy: long-term follow-up experience at a single institute. <i>BMC Urology</i> , 2017, 17, 62.	1.4	15

#	ARTICLE	IF	CITATIONS
73	Clinical Impact of Tumor-Infiltrating Lymphocytes and PD-L1-Positive Cells as Prognostic and Predictive Biomarkers in Urological Malignancies and Retroperitoneal Sarcoma. <i>Cancers</i> , 2020, 12, 3153.	3.7	15
74	Development and external validation of a preoperative nomogram for predicting pathological locally advanced disease of clinically localized upper urinary tract carcinoma. <i>Cancer Medicine</i> , 2020, 9, 3733-3741.	2.8	15
75	Proposed salvage treatment strategy for biochemical failure after radical prostatectomy in patients with prostate cancer: a retrospective study. <i>Radiation Oncology</i> , 2014, 9, 208.	2.7	14
76	Active surveillance for nonmuscle invasive bladder cancer. <i>Investigative and Clinical Urology</i> , 2016, 57, S4.	2.0	14
77	Spectrophotometric photodynamic detection involving extracorporeal treatment with hexaminolevulinate for bladder cancer cells in voided urine. <i>Journal of Cancer Research and Clinical Oncology</i> , 2017, 143, 2309-2316.	2.5	14
78	Transperineal template-guided saturation biopsy aimed at sampling one core for each milliliter of prostate volume: 103 cases requiring repeat prostate biopsy. <i>BMC Urology</i> , 2017, 17, 28.	1.4	14
79	Biological Behavior and Long-Term Outcomes of Carcinoma In Situ in Upper Urinary Tract Managed by Radical Nephroureterectomy. <i>Journal of Urology</i> , 2018, 199, 933-939.	0.4	14
80	Supplementary Oral Anamorelin Mitigates Anorexia and Skeletal Muscle Atrophy Induced by Gemcitabine Plus Cisplatin Systemic Chemotherapy in a Mouse Model. <i>Cancers</i> , 2020, 12, 1942.	3.7	14
81	A new risk stratification model for intravesical recurrence, disease progression, and cancer-specific death in patients with non-muscle invasive bladder cancer: the J-NICE risk tables. <i>International Journal of Clinical Oncology</i> , 2020, 25, 1364-1376.	2.2	14
82	ALA-induced fluorescence detection with photoresist-based microfluidic cell sorter for bladder cancer diagnosis. <i>Sensors and Actuators B: Chemical</i> , 2015, 213, 547-557.	7.8	13
83	Topical and systemic immunoreaction triggered by intravesical chemotherapy in an N-butyl-N-(4-hydroxybutyl) nitrosamine induced bladder cancer mouse model. <i>PLoS ONE</i> , 2017, 12, e0175494.	2.5	13
84	Effects of a new β -adrenoceptor agonist, vibegron, on neurogenic bladder dysfunction and remodeling in mice with spinal cord injury. <i>Neurourology and Urodynamics</i> , 2020, 39, 2120-2127.	1.5	13
85	Disabled Homolog 2 (DAB2) Protein in Tumor Microenvironment Correlates with Aggressive Phenotype in Human Urothelial Carcinoma of the Bladder. <i>Diagnostics</i> , 2020, 10, 54.	2.6	13
86	A Genitourinary Cancer-specific Scoring System for the Prediction of Survival in Patients with Bone Metastasis: A Retrospective Analysis of Prostate Cancer, Renal Cell Carcinoma, and Urothelial Carcinoma. <i>Anticancer Research</i> , 2018, 38, 3097-3103.	1.1	13
87	Changes in lower urinary tract symptoms and quality of life after salvage radiotherapy for biochemical recurrence of prostate cancer. <i>Radiotherapy and Oncology</i> , 2015, 115, 321-326.	0.6	12
88	Extended resection including adjacent organs and Ki-67 labeling index are prognostic factors in patients with retroperitoneal soft tissue sarcomas. <i>World Journal of Surgical Oncology</i> , 2016, 14, 43.	1.9	12
89	The efficacy and safety of docetaxel-based chemotherapy combined with dexamethasone 1 mg daily oral administration: JMT0 Pca 10-01 phase II trial. <i>Japanese Journal of Clinical Oncology</i> , 2017, 47, 247-251.	1.3	12
90	Trends in risk classification and primary therapy of Japanese patients with prostate cancer in Nara urological research and treatment group (NURTG) – comparison between 2004–2006, 2007–2009, and 2010–2012. <i>BMC Cancer</i> , 2017, 17, 616.	2.6	12

#	ARTICLE	IF	CITATIONS
91	Changes in lower urinary tract symptoms after iodine-125 brachytherapy for prostate cancer. <i>Clinical and Translational Radiation Oncology</i> , 2019, 14, 51-58.	1.7	12
92	Expression of peptide transporter 1 has a positive correlation in protoporphyrin IX accumulation induced by 5-aminolevulinic acid with photodynamic detection of non-small cell lung cancer and metastatic brain tumor specimens originating from non-small cell lung cancer. <i>Photodiagnosis and Photodynamic Therapy</i> , 2019, 25, 309-316.	2.6	12
93	Role of Nuclear Claudin-4 in Renal Cell Carcinoma. <i>International Journal of Molecular Sciences</i> , 2020, 21, 8340.	4.1	12
94	Urethral toxicity after LDR brachytherapy: Experience in Japan. <i>Brachytherapy</i> , 2015, 14, 131-135.	0.5	11
95	Clinical efficacy and safety of mirabegron and imidafenacin in women with overactive bladder: A randomized crossover study (the MICRO study). <i>Neurourology and Urodynamics</i> , 2017, 36, 1097-1103.	1.5	11
96	Aquaporin-2 plays an important role in water transportation through the bladder wall in rats. <i>Neurourology and Urodynamics</i> , 2018, 37, 2434-2440.	1.5	11
97	The impact of the definition of biochemical recurrence following salvage radiotherapy on outcomes and prognostication in patients with recurrent prostate cancer after radical prostatectomy: a comparative study of three definitions. <i>Prostate International</i> , 2019, 7, 47-53.	2.3	11
98	The primary therapy chosen for patients with localized prostate cancer between the university hospital and its affiliated hospitals in Nara Uro-oncological research group registration. <i>BMC Urology</i> , 2011, 11, 6.	1.4	10
99	Trends of risk classification and primary therapy for Japanese patients with prostate cancer in Nara Uro-Oncological Research Group (NUORG) – a comparison between 2004-2006 and 2007-2009. <i>BMC Cancer</i> , 2013, 13, 588.	2.6	10
100	Insignificant role of bacillus Calmette-Guérin maintenance therapy after complete transurethral resection of bladder tumor for intermediate- and high-risk non-muscle-invasive bladder cancer: Results from a randomized trial. <i>International Journal of Urology</i> , 2016, 23, 854-860.	1.0	10
101	Clinical utility of bioelectrical impedance analysis in patients with locoregional muscle invasive or metastatic urothelial carcinoma: a subanalysis of changes in body composition during neoadjuvant systemic chemotherapy. <i>Supportive Care in Cancer</i> , 2018, 26, 1077-1086.	2.2	10
102	Risk stratification by means of biological age-related factors better predicts cancer-specific survival than chronological age in patients with upper tract urothelial carcinoma: a multi-institutional database study. <i>Therapeutic Advances in Urology</i> , 2018, 10, 403-410.	2.0	10
103	Clinical Impact of the Increase in Immunosuppressive Cell-Related Gene Expression in Urine Sediment during Intravesical Bacillus Calmette-Guérin. <i>Diseases (Basel, Switzerland)</i> , 2019, 7, 44.	2.5	10
104	Evaluation of pro- and anti-tumor effects induced by three colony-stimulating factors, G-CSF, GM-CSF and M-CSF, in bladder cancer cells: Is G-CSF a friend of bladder cancer cells?. <i>International Journal of Oncology</i> , 2019, 54, 2237-2249.	3.3	10
105	Health utility and health-related quality of life of Japanese prostate cancer patients according to progression status measured using EQ-5D-5L and FACT-P. <i>Quality of Life Research</i> , 2019, 28, 2383-2391.	3.1	10
106	Down-Grading of Ipsilateral Hydronephrosis by Neoadjuvant Chemotherapy Correlates with Favorable Oncological Outcomes in Patients Undergoing Radical Nephroureterectomy for Ureteral Carcinoma. <i>Diagnostics</i> , 2020, 10, 10.	2.6	10
107	External validation of a genitourinary cancer-specific prognostic scoring system to predict survival for patients with bone metastasis (modified B-FOM scoring model): Comparison with other scoring models in terms of accuracy. <i>Journal of Bone Oncology</i> , 2021, 26, 100344.	2.4	10
108	Impact of Preoperative Abdominal Visceral Adipose Tissue Area and Nutritional Status on Renal Function After Donor Nephrectomy in Japanese Living Donors for Renal Transplantation. <i>Annals of Transplantation</i> , 2018, 23, 364-376.	0.9	10

#	ARTICLE	IF	CITATIONS
109	Bladder cancer prospective cohort study on high-risk non-muscle invasive bladder cancer after photodynamic diagnosis-assisted transurethral resection of the bladder tumor (BRIGHT study). <i>International Journal of Urology</i> , 2022, 29, 632-638.	1.0	10
110	5-Aminolevulinic acid overcomes hypoxia-induced radiation resistance by enhancing mitochondrial reactive oxygen species production in prostate cancer cells. <i>British Journal of Cancer</i> , 2022, 127, 350-363.	6.4	10
111	The optimal number of initial prostate biopsy cores in daily practice: a prospective study using the Nara Urological Research and Treatment Group nomogram. <i>BMC Research Notes</i> , 2015, 8, 689.	1.4	9
112	Clinical Significance of Tumor Size, Pathological Invasion Sites Including Urinary Collecting System and Clinically Detected Renal Vein Thrombus as Predictors for Recurrence in pT3a Localized Renal Cell Carcinoma. <i>Diagnostics</i> , 2020, 10, 154.	2.6	9
113	Photodynamic Diagnosis-Assisted En Bloc Transurethral Resection of Bladder Tumor for Nonmuscle Invasive Bladder Cancer: Short-Term Oncologic and Functional Outcomes. <i>Journal of Endourology</i> , 2021, 35, 319-327.	2.1	9
114	Tumor Location Based Segmentation in Upper-Tract Urothelial Carcinoma Impacts on the Urothelial Recurrence-Free Survival: A Multi-Institutional Database Study. <i>Current Urology</i> , 2020, 14, 183-190.	0.6	9
115	Arterial reconstruction using the donor's gonadal vein in living renal transplantation with multiple renal arteries: a case report and a literature review. <i>BMC Nephrology</i> , 2020, 21, 190.	1.8	9
116	Unexpected presentation and surgical salvage of transplant renal artery dissection caused by vascular clamping: a case report. <i>BMC Nephrology</i> , 2020, 21, 29.	1.8	9
117	Integrative assessment of clinicopathological parameters and the expression of PD-L1, PD-L2 and PD-1 in tumor cells of retroperitoneal sarcoma. <i>Oncology Letters</i> , 2020, 20, 1-1.	1.8	9
118	Response to Pembrolizumab After Dose-Reduced Cisplatin Plus Gemcitabine Chemotherapy Is Inferior to That After Carboplatin Plus Gemcitabine Chemotherapy in Cisplatin-Unfit Patients With Advanced Urothelial Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2022, 20, 196.e1-196.e9.	1.9	9
119	Potential biomarkers for the therapeutic efficacy of sorafenib, sunitinib and everolimus. <i>Oncology Reports</i> , 2017, 37, 227-234.	2.6	8
120	Urinary Nerve Growth Factor Can Predict Therapeutic Efficacy in Children With Overactive Bladder. <i>Urology</i> , 2017, 103, 214-217.	1.0	8
121	Atypical small acinar proliferation and two or more cores of high-grade intraepithelial neoplasia on a previous prostate biopsy are significant predictors of cancer during a transperineal template-guided saturation biopsy aimed at sampling one core for each 1 mL of prostate volume. <i>Research and Reports in Urology</i> , 2017, Volume 9, 187-193.	1.0	8
122	Comparison of chronological changes in urinary function in patients who underwent low-dose-rate brachytherapy for prostate cancer—A randomized controlled trial of alpha-1 adrenoceptor antagonist alone versus combination with cyclooxygenase-2 inhibitor. <i>Brachytherapy</i> , 2018, 17, 537-543.	0.5	8
123	Docetaxel-based chemotherapy combined with dexamethasone 1Âmg daily oral administration for castration-resistant prostate cancer: Long-term outcomes. <i>International Journal of Urology</i> , 2019, 26, 797-803.	1.0	8
124	Clinical benefit of early treatment with bone-modifying agents for preventing skeletal-related events in patients with genitourinary cancer with bone metastasis: A multi-institutional retrospective study. <i>International Journal of Urology</i> , 2019, 26, 630-637.	1.0	8
125	Quality of life in patients who underwent 125I brachytherapy, 125I brachytherapy combined with three-dimensional conformal radiation therapy, or intensity-modulated radiation therapy, for prostate cancer. <i>Journal of Radiation Research</i> , 2019, 60, 270-280.	1.6	8
126	Inhibition of Heparanase Expression Results in Suppression of Invasion, Migration and Adhesion Abilities of Bladder Cancer Cells. <i>International Journal of Molecular Sciences</i> , 2020, 21, 3789.	4.1	8

#	ARTICLE	IF	CITATIONS
127	Videoâ€urodynamic effects of vibegron, a new selective Î²3â€adrenoceptor agonist, on antimuscarinicâ€resistant neurogenic bladder dysfunction in patients with spina bifida. <i>International Journal of Urology</i> , 2022, 29, 76-81.	1.0	8
128	Significant Improvement of Prognosis After the Advent of Immune Checkpoint Inhibitors in Patients with Advanced, Unresectable, or Metastatic Urothelial Carcinoma: A Propensity Score Matching and Inverse Probability of Treatment Weighting Analysis on Real-World Data. <i>Cancer Management and Research</i> , 2022, Volume 14, 623-635.	1.9	8
129	Calculated Tumor Volume Is an Independent Predictor of Biochemical Recurrence in Patients Who Underwent Retropubic Radical Prostatectomy. <i>Advances in Urology</i> , 2012, 2012, 1-7.	1.3	7
130	Increased Urine Production Due to Leg Fluid Displacement Reduces Hours of Undisturbed Sleep. <i>LUTS: Lower Urinary Tract Symptoms</i> , 2018, 10, 253-258.	1.3	7
131	Overactive bladder induces transient hypertension. <i>BMC Research Notes</i> , 2018, 11, 196.	1.4	7
132	Urinary nerve growth factor can predict therapeutic efficacy in children with monosymptomatic nocturnal enuresis. <i>Neurourology and Urodynamics</i> , 2019, 38, 2311-2317.	1.5	7
133	The Preoperative Predictive Factors for Pathological T3a Upstaging of Clinical T1 Renal Cell Carcinoma. <i>Diagnostics</i> , 2019, 9, 76.	2.6	7
134	Tadalafil, a phosphodiesterase type 5 inhibitor, restores urethra and detrusor function in the initial phase of diabetes in rats. <i>LUTS: Lower Urinary Tract Symptoms</i> , 2019, 11, 241-247.	1.3	7
135	Fluorescent cystoscopy-assisted en bloc transurethral resection versus conventional transurethral resection in patients with non-muscle invasive bladder cancer: study protocol of a prospective, open-label, randomized control trial (the FLEBER study). <i>Trials</i> , 2021, 22, 136.	1.6	7
136	Hexylaminolevulinatâ€mediated fluorescent urine cytology with a novel automated detection technology for screening and surveillance of bladder cancer. <i>BJU International</i> , 2021, 128, 244-253.	2.5	7
137	Long-term Changes in Renal Function, Blood Electrolyte Levels, and Nutritional Indices after Radical Cystectomy and Ileal Conduit in Patients with Bladder Cancer. <i>Urology Journal</i> , 2019, 16, 145-151.	0.4	7
138	Prostate-specific antigen changes as a result of chlormadinone acetate administration to patients with benign prostatic hyperplasia: A retrospective multi-institutional study. <i>International Journal of Urology</i> , 2006, 13, 543-549.	1.0	6
139	The Effects of Chlormadinone Acetate on Lower Urinary Tract Symptoms and Erectile Functions of Patients with Benign Prostatic Hyperplasia: A Prospective Multicenter Clinical Study. <i>Advances in Urology</i> , 2013, 2013, 1-8.	1.3	6
140	A Randomized Control Trial Comparing the Efficacy of Antiandrogen Monotherapy: Flutamide vs. Bicalutamide. <i>Hormones and Cancer</i> , 2015, 6, 161-167.	4.9	6
141	Cognitive burden and polypharmacy in elderly Japanese patients treated with anticholinergics for an overactive bladder. <i>LUTS: Lower Urinary Tract Symptoms</i> , 2020, 12, 54-61.	1.3	6
142	Initial experience of complete laparoscopic radical nephroureterectomy combined with transvesical laparoscopic excision of distal ureter in patients with upper urinary tract cancer. <i>World Journal of Surgical Oncology</i> , 2020, 18, 104.	1.9	6
143	Optimal timing of ureteroscopy lithotripsy after the initial drainage treatment and risk factors for postoperative febrile urinary tract infection in patients with obstructive pyelonephritis: a retrospective study. <i>BMC Urology</i> , 2021, 21, 10.	1.4	6
144	The sustaining of fluorescence in photodynamic diagnosis after the administration of 5-aminolevulinic acid in carcinogen-induced bladder cancer orthotopic rat model and urothelial cancer cell lines. <i>Photodiagnosis and Photodynamic Therapy</i> , 2021, 34, 102309.	2.6	6

#	ARTICLE	IF	CITATIONS
145	Î³â€Klotho is correlated with resistance to docetaxel in castrationâ€resistant prostate cancer. <i>Oncology Letters</i> , 2020, 19, 2306-2316.	1.8	6
146	Clinical features of detrusor underactivity in elderly men without neurological disorders. <i>LUTS: Lower Urinary Tract Symptoms</i> , 2022, 14, 193-198.	1.3	6
147	Organ-Specific and Mixed Responses to Pembrolizumab in Patients with Unresectable or Metastatic Urothelial Carcinoma: A Multicenter Retrospective Study. <i>Cancers</i> , 2022, 14, 1735.	3.7	6
148	Chromophobe cell renal carcinoma with acquired cystic disease of the kidney in a long-term hemodialysis patient. <i>International Journal of Urology</i> , 2003, 10, 99-102.	1.0	5
149	Unexpected presentation of allograft dysfunction triggered by page kidney phenomenon immediately after kidney transplantation: a case report. <i>BMC Nephrology</i> , 2018, 19, 59.	1.8	5
150	Spectrophotometric photodynamic diagnosis of prostate cancer cells excreted in voided urine using 5-aminolevulinic acid. <i>Lasers in Medical Science</i> , 2018, 33, 1557-1563.	2.1	5
151	<p>Comparison of cancer detection rates by transrectal prostate biopsy for prostate cancer using two different nomograms based on patient’s age and prostate volume</p>. <i>Research and Reports in Urology</i> , 2019, Volume 11, 61-68.	1.0	5
152	Prognostic impact of tumorâ€infiltrating CD276/Foxp3â€positive lymphocytes and associated circulating cytokines in patients undergoing radical nephrectomy for localized renal cell carcinoma. <i>Oncology Letters</i> , 2019, 17, 4004-4010.	1.8	5
153	Analysis of quality of life after randomized controlled trial of alpha-1 adrenoceptor antagonist alone and in combination with cyclooxygenase-2 inhibitor in patients who underwent low-dose-rate brachytherapy for prostate cancer. <i>Journal of Contemporary Brachytherapy</i> , 2019, 11, 409-416.	0.9	5
154	Transient liver toxicity as a result of the oral administration of 5â€aminolevulinic acid for photodynamic diagnosis in patients with bladder cancer. <i>International Journal of Urology</i> , 2019, 26, 315-317.	1.0	5
155	Trends in treatment outcomes for retractile testis in Japanese boys: A singleâ€center study. <i>International Journal of Urology</i> , 2021, 28, 327-332.	1.0	5
156	Effect of Prolonged Duration of Transrectal Ultrasound-Guided Biopsy of the Prostate and Pre-Procedure Anxiety on Pain in Patients without Anesthesia. <i>Research and Reports in Urology</i> , 2021, Volume 13, 111-120.	1.0	5
157	Clinical outcomes after intravesical bacillus Calmetteâ€GuÃ©rin for the highestâ€risk nonâ€muscleâ€invasive bladder cancer newly defined in the Japanese Urological Association Guidelines 2019. <i>International Journal of Urology</i> , 2021, 28, 720-726.	1.0	5
158	Intravesical Bacillus Calmetteâ€GuÃ©rin Treatment for T1 High-Grade Non-Muscle Invasive Bladder Cancer with Divergent Differentiation or Variant Morphologies. <i>Cancers</i> , 2021, 13, 2615.	3.7	5
159	Trends in risk classification at diagnosis and choice of primary therapy for prostate cancer: An analysis of 10Â839 patients from the Nara Urological Research and Treatment Group registry between 2004 and 2015. <i>International Journal of Urology</i> , 2021, 28, 1164-1170.	1.0	5
160	Effects of low-dose insulin or a soluble guanylate cyclase activator on lower urinary tract dysfunction in streptozotocin-induced diabetic rats. <i>Life Sciences</i> , 2021, 286, 120001.	4.3	5
161	Remnant renal volume can predict prognosis of remnant renal function in kidney transplantation donors: a prospective observational study. <i>BMC Nephrology</i> , 2021, 22, 367.	1.8	5
162	Prognostication in Japanese patients with bacillus Calmetteâ€GuÃ©rinâ€unresponsive nonâ€muscleâ€invasive bladder cancer undergoing early radical cystectomy. <i>International Journal of Urology</i> , 2022, 29, 242-249.	1.0	5

#	ARTICLE	IF	CITATIONS
163	Prostatic volume and volume-adjusted prostate-specific antigen as predictive parameters for T1c prostate cancer. <i>Acta Urologica Japonica</i> , 2007, 53, 459-65.	0.1	5
164	Urinary schistosomiasis in a Japanese man. <i>International Journal of Urology</i> , 2004, 11, 563-566.	1.0	4
165	Risk factors of PSA progression and overall survival in patients with localized and locally advanced prostate cancer treated with primary androgen deprivation therapy. <i>BMC Cancer</i> , 2015, 15, 420.	2.6	4
166	Efficacy and safety of sequential use of everolimus in Japanese patients with advanced renal cell carcinoma after failure of first-line treatment with vascular endothelial growth factor receptor tyrosine kinase inhibitor: a multicenter phase II clinical trial. <i>Japanese Journal of Clinical Oncology</i> , 2017, 47, 551-559.	1.3	4
167	Successful salvage of allograft dysfunction triggered by transplant renal vein thrombosis immediately after kidney transplantation: a case report. <i>International Journal of Nephrology and Renovascular Disease</i> , 2018, Volume 11, 321-327.	1.8	4
168	Colony-stimulating factors detected in tumor cells and voided urine are potential prognostic markers for patients with muscle-invasive bladder cancer undergoing radical cystectomy. <i>Research and Reports in Urology</i> , 2018, Volume 10, 103-111.	1.0	4
169	Efficacy and safety of cytokines versus first-line sunitinib and second-line axitinib for patients with metastatic renal cell carcinoma (ESCAPE study): A study protocol for phase III randomized sequential open-label study. <i>Contemporary Clinical Trials Communications</i> , 2019, 15, 100403.	1.1	4
170	Clinical Significance of Postoperative Nutritional Status as a Prognostic Factor in Kidney Transplant Recipients. <i>Transplantation Proceedings</i> , 2019, 51, 1763-1772.	0.6	4
171	A Potential Application of Dynamic Contrast-Enhanced Magnetic Resonance Imaging Combined with Photodynamic Diagnosis for the Detection of Bladder Carcinoma in Situ: Toward the Future "MRI-PDD Fusion TURBT"™. <i>Diagnostics</i> , 2019, 9, 112.	2.6	4
172	Evaluation of Preoperative Abdominal Adipose Tissue, Inflammation-, Muscle Mass-, and Nutritional Status-based Prognostic Markers to Assess Renal Dysfunction in Living Kidney Donors. <i>Transplantation Proceedings</i> , 2019, 51, 1706-1716.	0.6	4
173	Intravesical treatment of chemotherapeutic agents sensitizes bacillus Calmette-Guerin by the modulation of the tumor immune environment. <i>Oncology Reports</i> , 2019, 41, 1863-1874.	2.6	4
174	The diagnostic utility of retroperitoneoscopic tissue biopsy for unresectable retroperitoneal lesions excluding urogenital cancers. <i>World Journal of Surgical Oncology</i> , 2019, 17, 35.	1.9	4
175	Trends in the Treatment Outcomes and Features of Cryptorchidism in Boys: A Single-Institute Experience. <i>Research and Reports in Urology</i> , 2020, Volume 12, 373-381.	1.0	4
176	Rapid multiplex PCR assay for simultaneous detection of <i>Neisseria gonorrhoeae</i> and <i>Chlamydia trachomatis</i> in genitourinary samples: A 30-minute assay. <i>Journal of Microbiological Methods</i> , 2021, 180, 106103.	1.6	4
177	Significance of the timing of ureteral ligation on prognosis during radical nephroureterectomy for upper urinary tract urothelial cancer. <i>International Journal of Urology</i> , 2021, 28, 208-214.	1.0	4
178	Intravesical Bacillus Calmette-Guerin treatment-induced sleep quality deterioration in patients with non-muscle invasive bladder cancer: functional outcome assessment based on a questionnaire survey and actigraphy. <i>Supportive Care in Cancer</i> , 2022, 30, 887-895.	2.2	4
179	Usefulness of clinical factors for diagnosing and differentiating types of testicular malposition in boys: A retrospective study. <i>International Journal of Urology</i> , 2022, 29, 57-64.	1.0	4
180	Hypomethylation of CLDN4 Gene Promoter Is Associated with Malignant Phenotype in Urinary Bladder Cancer. <i>International Journal of Molecular Sciences</i> , 2022, 23, 6516.	4.1	4

#	ARTICLE	IF	CITATIONS
181	Variations of transition zone volume and transition zone index after transurethral needle ablation for symptomatic benign prostatic hyperplasia. <i>International Journal of Urology</i> , 2003, 10, 392-397.	1.0	3
182	Orthotopic mouse model of renal pelvic cancer using a human bladder cancer cell line. <i>International Journal of Urology</i> , 2016, 23, 961-962.	1.0	3
183	Prostate-specific antigen bounce after 125I-brachytherapy for prostate cancer is a favorable prognosticator in patients who are biochemical recurrence-free at 4 years and correlates with testosterone. <i>Japanese Journal of Clinical Oncology</i> , 2020, 50, 58-65.	1.3	3
184	Periprostatic fat thickness quantified by preoperative magnetic resonance imaging is an independent risk factor for upstaging from cT1/2 to pT3 in robot-assisted radical prostatectomy. <i>International Journal of Urology</i> , 2020, 27, 1144-1149.	1.0	3
185	Daily salt intake is associated with leg edema and nocturnal urinary volume in elderly men. <i>Neurourology and Urodynamics</i> , 2020, 39, 1550-1556.	1.5	3
186	Bacillus Calmette-Guérin-unresponsive non-muscle invasive bladder cancer outcomes in patients without radical cystectomy. <i>International Journal of Clinical Oncology</i> , 2021, 26, 2104-2112.	2.2	3
187	A phase III, multicenter, randomized, controlled study of maximum androgen blockade with versus without zoledronic acid in treatment-naïve prostate cancer patients with bone metastases: Results of ZAPCA study. <i>Journal of Clinical Oncology</i> , 2015, 33, 150-150.	1.6	3
188	The effects of choreito on a model of nocturnal polyuria using Dahl salt-sensitive rats. <i>LUTS: Lower Urinary Tract Symptoms</i> , 2022, 14, 122-128.	1.3	3
189	Clinical and emotional factors for the acceptance or refusal of deceased donor kidney transplantation in patients on waiting lists during the coronavirus disease 2019 pandemic. <i>International Journal of Urology</i> , 2022, 29, 470-472.	1.0	3
190	A prospective, single-arm trial of fluorescent ureteroscopy-assisted thulium-holmium:YAG dual laser ablation for upper urinary tract cancer: Study protocol of the FLUAM trial. <i>Contemporary Clinical Trials Communications</i> , 2022, 26, 100902.	1.1	3
191	Preliminary Experience with Low-dose Desmopressin Treatment and Urinary Arginine Vasopressin Concentration as a Response Predictor for Patients with Nocturia with Nocturnal Polyuria. <i>LUTS: Lower Urinary Tract Symptoms</i> , 2014, 6, 107-112.	1.3	2
192	Oncological outcome, complications, lower urinary tract symptoms, and health-related quality of life after low-dose-rate salvage brachytherapy for recurrent prostate cancer following primary radiotherapy: a report of 8 cases. <i>Journal of Contemporary Brachytherapy</i> , 2017, 4, 364-372.	0.9	2
193	Quality of life worsened the most severely in patients immediately after intensity-modulated radiation therapy for prostate cancer. <i>Research and Reports in Urology</i> , 2018, Volume 10, 169-180.	1.0	2
194	Response to flutamide, as second-line therapy after bicalutamide, predicts efficacy of abiraterone, not that of enzalutamide. <i>BMC Research Notes</i> , 2018, 11, 342.	1.4	2
195	Significant lack of urine-based biomarkers to replace cystoscopy for the surveillance of non-muscle invasive bladder cancer. <i>Translational Andrology and Urology</i> , 2019, 8, S332-S334.	1.4	2
196	Amrubicin is effective against small cell carcinoma of the prostate as a second-line chemotherapeutic agent: A case report. <i>IJU Case Reports</i> , 2019, 2, 133-136.	0.3	2
197	Animal model of local tumor recurrence after resection using the murine MBT2 bladder cancer cell line in syngeneic C3H mice. <i>International Journal of Urology</i> , 2019, 26, 300-302.	1.0	2
198	Factors contributing to the ceiling effect of the EQ-5D-5L: an analysis of patients with prostate cancer judged "no-problems". <i>Quality of Life Research</i> , 2020, 29, 755-763.	3.1	2

#	ARTICLE	IF	CITATIONS
199	Biochemical control of the combination of cyclooxygenase-2 inhibitor and 125 I-Brachytherapy for prostate cancer: Post hoc analysis of an open-label controlled randomized trial. <i>International Journal of Urology</i> , 2020, 27, 755-759.	1.0	2
200	Trends in treatment outcomes of hydrocele in Japanese children: A single-institute experience. <i>International Journal of Urology</i> , 2020, 27, 946-950.	1.0	2
201	Coverage of the external prostatic region by the hybrid method compared with the conventional method of prostate low-dose-rate brachytherapy: A randomized controlled study. <i>International Journal of Urology</i> , 2020, 27, 1013-1017.	1.0	2
202	Sodium plays an important role in the absorption of intravesical fluid. <i>LUTS: Lower Urinary Tract Symptoms</i> , 2021, 13, 177-182.	1.3	2
203	Appropriate Number of Docetaxel Cycles in Castration-Resistant Prostate Cancer Patients Considering Peripheral Neuropathy and Oncological Control. <i>Chemotherapy</i> , 2020, 65, 1-6.	1.6	2
204	Non-ischemic, Non-renalorrhaphy Laparoscopic Partial Nephrectomy Using a Microwave Tissue Coagulator for Small Renal Tumors. <i>Journal of Microwave Surgery</i> , 2016, 34, 1-6.	0.3	2
205	A clinicopathological review of 35 with hemodialysis patients renal cell carcinomas. <i>Nihon Toseki Igakkai Zasshi</i> , 2005, 38, 1589-1594.	0.1	2
206	Personalized peptide vaccination for castration-resistant prostate cancer progressing after docetaxel chemotherapy: A randomized, double-blind, placebo-controlled, phase III trial. <i>Journal of Clinical Oncology</i> , 2019, 37, 5033-5033.	1.6	2
207	Inhibitory Effect of Orally Administered 5-Aminolevulinic Acid on Prostate Carcinogenesis in the FVB-Transgenic Adenocarcinoma of a Mouse Prostate (FVB-TRAMP) Model. <i>Asian Pacific Journal of Cancer Prevention</i> , 2020, 21, 3743-3749.	1.2	2
208	Impact of neoadjuvant androgen deprivation therapy on postimplant prostate D90 and prostate volume after low-dose-rate brachytherapy for localized prostate cancer. <i>International Journal of Urology</i> , 2021, , .	1.0	2
209	Efficacy of pembrolizumab rechallenge for metastatic urothelial carcinoma. <i>IJU Case Reports</i> , 0, , .	0.3	2
210	Tissue levels of pyrimidine nucleoside phosphorylase activity in human and rodent bladder cancer and normal bladder tissue. <i>International Journal of Urology</i> , 2007, 14, 754-759.	1.0	1
211	Pretreatment assessment and perioperative nutritional interventions for patients with bladder cancer undergoing radical cystectomy. <i>Translational Andrology and Urology</i> , 2018, 7, 984-986.	1.4	1
212	Localized prostate cancer with pelvic arteriovenous malformation treated with low-dose-rate brachytherapy after transcatheter embolization: Two case reports. <i>IJU Case Reports</i> , 2019, 2, 90-94.	0.3	1
213	<p>Comparison of the Safety and Efficacy of Photoselective Vaporization of the Prostate (PVP) and Transurethral Enucleation with a Bipolar System (TUEB): A Single-Center Retrospective Study</p>. <i>Research and Reports in Urology</i> , 2020, Volume 12, 569-575.	1.0	1
214	Evaluating the optimal technique of transperineal template-guided saturation biopsy in patients requiring repeat prostate biopsy. <i>International Journal of Urology</i> , 2020, 27, 1157-1158.	1.0	1
215	A prospective study of oral 5-aminolevulinic acid to prevent adverse events in patients with localized prostate cancer undergoing low-dose-rate brachytherapy: Protocol of the AMBER study. <i>Contemporary Clinical Trials Communications</i> , 2020, 19, 100593.	1.1	1
216	Impact of Radical Nephrectomy and Partial Nephrectomy on Actual Estimated Overall Survival Compared to Life Expectancy in Patients with Renal Cell Carcinoma. <i>Research and Reports in Urology</i> , 2021, Volume 13, 155-165.	1.0	1

#	ARTICLE	IF	CITATIONS
217	Factors affecting urinary frequency after low-dose-rate brachytherapy for prostate cancer. LUTS: Lower Urinary Tract Symptoms, 2021, , .	1.3	1
218	Comparison of disease-specific quality of life in prostate cancer patients treated with low-dose-rate brachytherapy: A randomized controlled trial of silodosin versus naftopidil. International Journal of Urology, 2021, 28, 1171-1176.	1.0	1
219	Assessment of bladder function for stabilizing urinary volume overnight with recording of brain waves (ABSORB study). LUTS: Lower Urinary Tract Symptoms, 2021, , .	1.3	1
220	Isoflavones in Japanese and Caucasian men with prostate cancer in Hawaii.. Journal of Clinical Oncology, 2014, 32, 241-241.	1.6	1
221	Temsirolimus-induced interstitial lung disease as an on-target effect in patients with metastatic renal cell carcinoma.. Journal of Clinical Oncology, 2017, 35, e16086-e16086.	1.6	1
222	Lack of evidence regarding bone metastases of genitourinary cancers: interventions by surgery, radiotherapy, and bone-targeted systemic therapy. Annals of Translational Medicine, 2019, 7, S92-S92.	1.7	1
223	Erectile dysfunction and sexual quality of life in patients who underwent low-dose-rate brachytherapy alone for prostate cancer. Andrologia, 2022, 54, e14288.	2.1	1
224	Successful treatment of arteriovenous fistula-related venous hypertension: stenting of metal stents at central vein stenosis. Nihon Toseki Igakkai Zasshi, 2004, 37, 1535-1540.	0.1	1
225	Clinical Impact of Subclinical Interstitial Fibrosis or Tubular Atrophy in 1-Hour Allograft Biopsy for Remnant Renal Function in Living Kidney Donors: A Prospective Observational Study. Transplantation Proceedings, 2021, 53, 2833-2840.	0.6	1
226	Relevance of the perioperative edema index measured by bioelectrical impedance analysis for prediction of cardiovascular disease in living-donor kidney transplantation. International Journal of Urology, 2022, , .	1.0	1
227	Identification of diagnostic serum biomarkers for Hunner-type interstitial cystitis. LUTS: Lower Urinary Tract Symptoms, 2022, 14, 334-340.	1.3	1
228	Mirabegron Reduces Urinary Frequency and Improves Overactive Bladder Symptoms at 3 Months After 125I-brachytherapy for Prostate Cancer: An Open-Labelled, Randomized, Non-Placebo-Controlled Study. Urology, 2022, 161, 87-92.	1.0	1
229	Urodynamics findings pre- and post-untethering surgery in children with filum lipoma: A single-institution experience. International Journal of Urology, 0, , .	1.0	1
230	Site-specific Risk Stratification Models for Postoperative Recurrence and Survival Prediction in Patients with Upper Tract Urothelial Carcinoma Undergoing Radical Nephroureterectomy: Better Stratification for Adjuvant Therapy. European Urology Open Science, 2022, 41, 95-104.	0.4	1
231	Evaluation of metastatic potential of prostate cancer. Oncology Reviews, 2011, 5, 103-107.	1.8	0
232	Photoresist-based Microfluidic Cell Sorter for Photodynamic Urine Diagnosis. Procedia Engineering, 2014, 87, 62-65.	1.2	0
233	Reply. Urology, 2014, 84, 896-897.	1.0	0
234	The Efficacy of Bulbar Urethral Mobilization for Anastomotic Anterior Urethroplasty in a Case With Recurrent Anterior Urethral Stricture. Urology Case Reports, 2014, 2, 105-107.	0.3	0

#	ARTICLE	IF	CITATIONS
235	Effect of bladder distension on arginine vasopressin secretion in rats. BMC Research Notes, 2019, 12, 72.	1.4	0
236	Rationale, design, and methods of electroencephalography-based investigation of the effects of oral desmopressin on improving slow-wave sleep time in nocturnal polyuria patients (the DISTINCT study): protocol for a single-arm, open-label, single-assignment trial. BMC Urology, 2020, 20, 96.	1.4	0
237	Reply to "Predictors of Recurrence for T3a RCC: A Recurring Conundrum". Diagnostics, 2020, 10, 984.	2.6	0
238	Is Endoscopic Transurethral Incision Really Effective for Boys with Refractory Daytime Incontinence? Research and Reports in Urology, 2020, Volume 12, 273-277.	1.0	0
239	A Japanese man with spina bifida who successfully fathered a child following fertility treatment. IJU Case Reports, 2020, 3, 90-92.	0.3	0
240	Long-term chronological changes in renal function and functional renal volume after nephron-sparing surgery: A prospective observational study. International Journal of Urology, 2021, 28, 1112-1119.	1.0	0
241	Clinical significance of bladder deformity for intravesical recurrence after Bacillus Calmette-Guérin treatment. International Journal of Urology, 2021, 28, 1304-1305.	1.0	0
242	Intermittent testicular torsion diagnosed by evaluating the rotatability of testis with ultrasonography: a case report. Choonpa Igaku, 2021, 48, 287-291.	0.0	0
243	S14-2 Risk factors and prediction of recurrence in superficial bladder cancer(Symposium) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 5	0.1	0
244	Extreme effect of parathyroidectomy for tumoral calsinosis with secondary hyperparathyroidism in 3 cases. Nihon Toseki Igakkai Zasshi, 2006, 39, 1415-1420.	0.1	0
245	WS1-4-3 Circadian Variation of Body Water Distribution in Patients with Nocturnal Polyuria : Assessment by Bioelectric Impedance Analysis (BIA)(Urodynamic, Prostate and Urethra). Japanese Journal of Urology, 2008, 99, 151.	0.1	0
246	The surgical outcomes of non-ischemic partial nephrectomy using a microwave tissue coagulator for stage T1 renal cell carcinoma. Journal of Microwave Surgery, 2010, 28, 69-74.	0.3	0
247	Successful double filtration plasmapheresis treatment in an Rh(E)-incompatible pregnancy. Nihon Toseki Igakkai Zasshi, 2012, 45, 363-366.	0.1	0
248	Multicenter phase II clinical trial of everolimus in Japanese patients with unresectable or metastatic renal cell carcinoma (mRCC) after failure of treatment with first-line tyrosine kinase inhibitor (TKI) therapy.. Journal of Clinical Oncology, 2014, 32, 455-455.	1.6	0
249	Effects of hemodialysis on free/total prostate specific antigen.. Nihon Toseki Igakkai Zasshi, 1999, 32, 357-361.	0.1	0
250	A peritoneal dialysis patient with a right-sided aortic arch died of bronchial obstruction due to the enlargement of a Kommerell's diverticulum after laparoscopic nephrectomy for renal cell carcinoma. Nihon Toseki Igakkai Zasshi, 2016, 49, 247-252.	0.1	0
251	A case in which colonic perforation occurred twice 10 years after cadaveric kidney transplantation. Nihon Toseki Igakkai Zasshi, 2019, 52, 551-557.	0.1	0
252	Analysis of serum amyloid β 2 microglobulin from hemodialysis patients using liquid chromatography/mass spectrometry. Nihon Toseki Igakkai Zasshi, 2019, 52, 451-455.	0.1	0

#	ARTICLE	IF	CITATIONS
253	Potential biological and clinical benefit of prostate-directed interventions in patients with metastatic prostate cancer. <i>Annals of Translational Medicine</i> , 2019, 7, S46-S46.	1.7	0
254	Photodynamic Technology for Prostate Cancer. <i>Nippon Laser Igakkaishi</i> , 2019, 40, 87-92.	0.0	0
255	Impact of carcinoma in situ on the outcome of intravesical Bacillus Calmette-Guérin therapy for non-muscle-invasive bladder cancer: a comparative analysis of large real-world data. <i>International Journal of Clinical Oncology</i> , 2022, , 1.	2.2	0
256	Segmental testicular infarction diagnosed using microvascular imaging: a case report. <i>Choonpa Igaku</i> , 2022, 49, 159-164.	0.0	0
257	Reduction of residual tumors by photodynamic diagnosis-assisted TURBT using 5-aminolevulinic acid for high-risk nonmuscle-invasive bladder cancer (BRIGHT study).. <i>Journal of Clinical Oncology</i> , 2022, 40, 489-489.	1.6	0
258	Association between urine 6-sulfatoxy-melatonin level and intravesical Bacillus Calmette-Guerin treatment-induced sleep quality deterioration in patients with non-muscle invasive bladder cancer. <i>Supportive Care in Cancer</i> , 2022, , 1.	2.2	0
259	Efficacy of medical expulsive therapy using the traditional <scp>Japanese</scp> medicine (kampo) choreito for the spontaneous passage of proximal ureteric stones: A retrospective analysis. <i>Traditional & Kampo Medicine</i> , 0, , .	0.6	0
260	Clinical impact of perioperative body fluid management in kidney transplant recipients. <i>Nihon Toseki Igakkai Zasshi</i> , 2022, 55, 379-385.	0.1	0